A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Healthy Subjects Clinical Trial

Official title:

An Open-Label, Fixed Sequence Study in Healthy Post Menopausal Female Subjects to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05551897
• Other study ID #: D8532C00003
• Secondary ID: 2022-002011-35
• Status: Completed
• Phase: Phase 1
• Start date: October 4, 2022
• Est. completion date: December 28, 2022

Study information

• Verified date: January 2023
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be conducted in healthy post-menopausal female subjects to assess the pharmacokinetics (PK) of Camizestrant (AZD9833) when administered alone and in combination with Itraconazole.

Description:

This open-label, fixed sequence study will comprise of: - A screening period of 28 days; - A fixed sequence of three treatment period: Treatment Period 1: Camizestrant only, Treatment Period 2: Itraconazole only, Treatment Period 3: Camizestrant and Itraconazole in combination. • A Follow-up Visit at 7 to 14 days after the last Camizestrant PK sample in Period 3. There will be a washout period of 7 to 10 days between Period 1 and Period 2. Each subject will be involved in the study for approximately 8 or 9 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: December 28, 2022
• Est. primary completion date: December 28, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

• Healthy post-menopausal female subjects aged 50 to 70 years with suitable veins for cannulation or repeated venipuncture
• Subjects must be post-menopausal by fulfilling the following criterion:

a. Post-menopausal defined as amenorrhea for at least 12 months or more without an alternative medical or surgical cause and confirmed by an FSH result of = 30 IU/L.

• Have a body mass index (BMI) between 19 and 35 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
• Must agree to not use warfarin or phenytoin (and other coumarin-derived vitamin K antagonist anticoagulants) from screening, and for 2 weeks after last administration of the study drug.

Exclusion Criteria:

• History of any clinically significant disease or disorder which may either put the subject at risk because of participation in the study
• History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• History of clinically significant cardiovascular, chronic respiratory, neurological, or psychiatric disorder
• History of or ongoing clinically significant visual disturbances including but not limited to visual hallucinations, migraine with visual symptoms, blurred vision, frequent floaters/flashes associated with other symptoms such as dizziness
• Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of the study drug.
• Any clinically significant abnormal findings in vital signs or 12-lead Electrocardiogram (ECG).
• Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and Human Immunodeficiency Virus (HIV) antibody.
• Known or suspected history of drug or alcohol abuse.
• History of significant allergy or hypersensitivity.
• Current smokers or those who have smoked or used nicotine products (including e-cigarettes and nicotine replacement products) within the 3 months prior to screening.
• Use of systemic oestrogen-containing hormone replacement therapy within 6 months prior to first dose in the study.
• Have any active indication for therapeutic anticoagulation, and/or having taken an anticoagulant within 14 days of beginning the study.
• Any of the following signs or confirmation of COVID-19 infection:

1. Subject has a positive test for SARS-CoV-2 prior to admission.

2. Clinical signs and symptoms consistent with COVID-19 (eg, fever, dry cough, dyspnoea, sore throat, fatigue) or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or at admission.

3. Subject has been previously hospitalized with COVID-19 infection within the last 12 months.

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• Camizestrant
Subjects will be administered a single oral dose of Camizestrant on Day 1 of treatment period 1 and treatment period 3.
• Itraconazole
Subjects will be administered Itraconazole twice a day on Day 1 and once daily on Day 2 and Day 3 of treatment period 2, and once daily on Day 1, 2 and 3 of treatment period 3.

Locations

Country	Name	City	State
United Kingdom	Research Site	Harrow

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	Parexel

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under plasma concentration time curve from zero to infinity (AUCinf) of Camizestrant	To assess the effect of Itraconazole on AUCinf of Camizestrant.	Day 1 to Day 4 (Period 1 and Period 3)
Primary	Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) of Camizestrant	To assess the effect of Itraconazole on AUClast of Camizestrant.	Day 1 to Day 4 (Period 1 and Period 3)
Primary	Maximum observed plasma (peak) drug concentration (Cmax) of Camizestrant	To assess the effect of Itraconazole on Cmax of Camizestrant.	Day 1 to Day 4 (Period 1 and Period 3)
Secondary	Number of subjects with adverse events (AEs) and serious adverse events (SAEs)	Safety and tolerability of Camizestrant alone and in combination with Itraconazole will be assessed.	From Screening (Day -28 to Day -2) up to follow-up visit (7 to 14 days after last Pharmacokinetic Sample) [approximately 9 weeks]
Secondary	Number of subjects with adverse events leading to the discontinuation of study drug (DAEs)	Number of subjects who discontinue the study drug due to adverse events will be assessed.	From Day 1 (period 1) up to follow-up visit (7 to 14 days after last Pharmacokinetic Sample) [approximately 9 weeks]